TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21173173
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg per os once daily for 5 days
Study: 21173173
Drug: Clindamycin 300
Normalized name: clindamycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300 mg per os four times daily for 5 days
Study: 15383007
Drug: Eprosartan (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (600 mg)
Study: 12883365
Drug: SRL172 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL172 + low-dose IL-2
Study: 10701731
Drug: Glutamine suspension
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine suspension (16 g in 240 ml normal saline)
Study: 9412131
Drug: Powdered microcrystalline
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered microcrystalline cellulose dosed 5 g/day for three months
Study: 8242128
Drug: Corticotrophin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotrophin-releasing hormone (CRF) test (1 μg/kg body weight)
Study: 3519041
Drug: High-dose alizapride
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alizapride (4 mg/kg X five doses)
Study: 3519041
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (2 mg/kg X five doses)
Study: 26315810
Drug: Crushed ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed ticagrelor 180 mg (2 tablets, semi-upright position)
Study: 26315810
Drug: Integral ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integral ticagrelor 180 mg (2 tablets, supine position)
Study: 20070961
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol (800 microg at the time of peritoneal incision)
Study: 20070961
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin infusion (after delivery of the neonate)
Study: 18788841
Drug: Flumazenil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.5 mg or 1.0 mg)
Study: 10068575
Drug: Amprenavir (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir (1200 mg) alone
Study: 10068575
Drug: Amprenavir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir with zidovudine (300 mg) plus lamivudine (150 mg)
Study: 10068575
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (Amprenavir, zidovudine, and lamivudine)
Study: 6770760
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (30-60 mg/kg per day)
Study: 6770760
Drug: Phenobarbitone (3-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (3-6 mg/kg per day)
Study: 16232370
Drug: CSII (Continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII (Continuous Subcutaneous Insulin Infusion) in group CSII-1
Study: 16232370
Drug: Multiple Injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple Injections (MI) in group MI-1
Study: 12198064
Drug: ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.5% plus clonidine 7.5 microg/mL (Group 3; n = 13)
Study: 12198064
Drug: ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.5% plus clonidine 7.5 microg/mL (Group 3)
Study: 10438346
Drug: Lamivudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (150 mg 2x/day)
Study: 10438346
Drug: Lamivudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (150 mg 2x/day) plus loviride (100 mg 3x/day)
Study: 7784415
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg for 8 days)
Study: 27102506
Drug: MRA regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRA regimen with potassium canrenoate (200 mg IV bolus) followed by spironolactone (25 mg once daily for 6 months)
Study: 23981186
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy with a bolus calculator
Study: 16167290
Drug: 0.2% sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% sodium naproxen, administered three times a day for 14 days
Study: 16167290
Drug: 0.1% diclofenac,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% diclofenac, administered three times a day for 14 days
Study: 9384465
Drug: Ro 48-6791
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 48-6791 (0.1-0.3-1 mg and 1-2-3 mg doses)
Study: 9384465
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg kg(-1))
Study: 1472793
Drug: PSK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSK treatment
Study: 6610736
Drug: PRP-D vaccine
Normalized name: Hib (PRP-D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-D vaccine (20 micrograms, two injections separated by one month)
Study: 6610736
Drug: PRP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP vaccine (20 micrograms, single injection)
Study: 6610736
Drug: PRP-D vaccine
Normalized name: Hib (PRP-D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-D vaccine and PRP vaccine
Study: 30734018
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (standard care plus twice-weekly high-intensity aerobic exercise and resistance training)
Study: 26582269
Drug: Preparation counseling
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation counseling
Study: 26582269
Drug: Preparation nicotine
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation nicotine patch
Study: 26582269
Drug: Preparation nicotine
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation nicotine gum
Study: 26582269
Drug: 16 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 weeks of combination nicotine replacement therapy (nicotine patch + nicotine gum)
Study: 26582269
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of combination nicotine replacement therapy (nicotine patch + nicotine gum)
Study: 24612282
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate 0.1% ointment (MPA), applied once daily with ¼ fingertip unit for 5 days
Study: 24612282
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate 0.1% ointment (MPA)
Study: 22049995
Drug: Interviewer-administered CPQ(8-10)
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered CPQ(8-10)
Study: 22049995
Drug: Interviewer-administered CPQ(11-14)
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered CPQ(11-14)
Study: 22049995
Drug: Self-administered CPQ(8-10)
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered CPQ(8-10)
Study: 22049995
Drug: Self-administered CPQ(11-14)
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered CPQ(11-14)
Study: 14757913
Drug: 48 mg
Normalized name: betaine 648 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 mg betahistine
Study: 2014943
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy (325 mg, alternate-day)
Study: 6385507
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg cimetidine daily in four separate doses (q.i.d.)
Study: 6385507
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine twice a day (b.i.d.)
Study: 31819291
Drug: Household costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household costs associated with P. vivax malaria treatment
Study: 20652432
Drug: Tuna oil
Normalized name: tuna oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuna oil (210 mg EPA, 30 mg DPA, 810 mg DHA)
Study: 20652432
Drug: Seal oil
Normalized name: seal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seal oil (340 mg EPA, 230 mg DPA, 450 mg DHA)
Study: 10493085
Drug: Paroxetine 20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20-50 mg daily
Study: 1767251
Drug: Phenoxymethylpenicillin dosed
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin dosed three times daily
Study: 25716539
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg single oral dosage
Study: 15665769
Drug: Fluvastatin (Lescol)
Normalized name: fluvastatin Oral Capsule [Lescol]
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin (Lescol) 40 mg/day or 80 mg/day
Study: 10423657
Drug: Cetirizine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (0.2 mg/kg once daily for 28 days)
Study: 10423657
Drug: Loratadine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (0.2 mg/kg once daily for 28 days)
Study: 8538704
Drug: Acellular DTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular DTP vaccine (SmithKline Beecham)
Study: 8538704
Drug: Acellular DTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular DTP vaccine (Chiron Biocine)
Study: 1866164
Drug: Cytostatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytostatic treatment (Cyclophosphamide, Vincristine, Ftorafur) for 3 months for Group 1 and lifelong systemic treatment for Group 2.
Study: 1866164
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (67 patients) who had not received chemotherapeutic treatment.
Study: 7048748
Drug: Lonazolac-Ca (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lonazolac-Ca (200 mg three times daily)
Study: 7048748
Drug: Naproxen (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250 mg twice daily plus 1 placebo capsule)
Study: 18679606
Drug: Modified Xufu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Xufu Zhuyu Decoction (XFZY) plus conventional comprehensive Western medicine
Study: 18679606
Drug: Conventional comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional comprehensive Western medicine
Study: 12227873
Drug: Isotretinoin 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 0.1% w/w and erythromycin 4.0% w/w gel (Double Strength Isotrexin) once daily
Study: 12227873
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 5.0% w/w and erythromycin 3.0% w/w gel (Benzamycin) twice daily
Study: 12227873
Drug: Isotretinoin/erythromycin gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin/erythromycin gel
Study: 12227873
Drug: Benzoyl peroxide/erythromycin
Normalized name: BENZOYL PEROXIDE/ERYTHROMYCIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl peroxide/erythromycin gel
Study: 10215736
Drug: Aspirin 1
Normalized name: aspirin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1 g b.d. for 14 days
Study: 2213396
Drug: Ibuprofen suspension
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen suspension at a dosage of 30 to 40 mg/kg/day
Study: 2213396
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at a dosage of 60 to 80 mg/kg/day
Study: 2213396
Drug: Ibuprofen suspension
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen suspension (30, 40, and 50 mg/kg/day) in a 24-week open trial
Study: 11826230
Drug: Ibuprofen suspension
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen suspension
Study: 31888938
Drug: Short text
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short text messages three times a week for 6 months designed to improve medication adherence.
Study: 28872920
Drug: Edaravone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (60 mg intravenous)
Study: 21849011
Drug: Discontinue medication
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue medication (Group A)
Study: 21849011
Drug: 2-month additional
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2-month additional medication (Group B)
Study: 21849011
Drug: 5-month additional
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-month additional medication (Group C)
Study: 11482041
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole, amoxicillin, clarithromycin)
Study: 11482041
Drug: Omeprazole plus
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole plus antibiotic placebo
Study: 11482041
Drug: Ranitidine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine placebo (after initial treatment)
Study: 11482041
Drug: Ranitidine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (after initial treatment)
Study: 9824409
Drug: SIT (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT (subcutaneous immunotherapy) for birch pollen for 12, 24, or 36 months
Study: 9824409
Drug: SIT (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT (subcutaneous immunotherapy) for birch pollen
Study: 2496052
Drug: abortive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: abortive therapy with ergotamine tartrate plus caffeine (standard abortive therapy)
Study: 2496052
Drug: standard abortive
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard abortive therapy accompanied by a brief educational intervention
Study: 26182059
Drug: Kinect-based exergame,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinect-based exergame, played once or twice a week, up to a total of 24 times
Study: 28575467
Drug: Doxepin 6
Normalized name: doxepin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 6 mg
Study: 21722958
Drug: Doxepin 50
Normalized name: doxepin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 50 mg
Study: 8602314
Drug: Estrogen-progestin preparation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-progestin preparation
Study: 1761336
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral aspirin
Study: 7067071
Drug: Intranasal flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal flunisolide (300 micrograms/day)
Study: 3882355
Drug: trimethoprim-sulfamethopyrazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim-sulfamethopyrazine (2 capsules of 250 mg trimethoprim + 200 mg sulfamethopyrazine per capsule on the 1st day and 1 capsule for the following 14 days)
Study: 3882355
Drug: trimethoprim-sulfamethoxazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim-sulfamethoxazole (2 capsules of trimethoprim 80 mg + sulfamethoxazole 400 mg per capsule twice daily for 15 days)
Study: 24926954
Drug: Intraduodenal L-tryptophan
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal L-tryptophan (L-Trp) at 0.075 kcal/min (total 6.75 kcal)
Study: 24926954
Drug: Intraduodenal L-tryptophan
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal L-tryptophan (L-Trp) at 0.15 kcal/min (total 13.5 kcal)
Study: 18419949
Drug: Urapidil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (5 mg) injected into coronary artery after 10 minutes of nitroglycerin (200 microg) injection.
Study: 18419949
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (5 ml) injected into coronary artery after 10 minutes of nitroglycerin (200 microg) injection (Control group).
Study: 16227864
Drug: Multiple interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple interventions assessed alone or in combination
Study: 10394020
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B colloidal dispersion (ABCD), median cumulative dose 4050 mg, median duration 18 days
Study: 7555617
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg or 25 mg ketoprofen
Study: 7555617
Drug: 275 mg
Normalized name: kava root 275 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 275 mg naproxen sodium
Study: 72290
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oxprenolol
Study: 28114922
Drug: Twice-weekly home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly home monitoring of symptoms (CFRSD-CRISS and FEV1)
Study: 25669933
Drug: Everolimus combined
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus combined with lower dose tacrolimus
Study: 25669933
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (combination regimen minus everolimus)
Study: 19479852
Drug: anti-IFNalpha monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-IFNalpha monoclonal antibody (mAb) therapy
Study: 14656555
Drug: Comorbid PTSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comorbid PTSD and AD treatment group
Study: 14656555
Drug: PTSD alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTSD alone treatment group
Study: 14656555
Drug: AD alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD alone treatment group
Study: 29385578
Drug: NRT patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT patches with prescribed doses of oral NRT
Study: 15599137
Drug: Bupivacaine (0.5%)
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine (0.5%) + S(+) ketamine (75 mg)
Study: 15599137
Drug: Bupivacaine (0.5%)
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine (0.5%) + Ketorolac (60 mg)
Study: 8130055
Drug: Alfentanil 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 1 mg as a bolus i.v. injection 15 s before propofol
Study: 31299077
Drug: ELISA threshold
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA threshold of 51.7 ELISA units/mL
Study: 28701597
Drug: Milrinone low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Milrinone low-dose infusion at 0.375 μg/kg/min
Study: 28701597
Drug: Milrinone medium-dose
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone medium-dose infusion at 0.5 μg/kg/min
Study: 28701597
Drug: Milrinone high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone high-dose infusion at 0.75 μg/kg/min
Study: 25307771
Drug: 10% neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% neutral buffered formalin solution (NBF)
Study: 21929764
Drug: Terlipressin (TP)
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (TP) 1 μg/kg/hour
Study: 17068314
Drug: Sertraline (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (selective serotonin reuptake inhibitor); specific dosage and duration not mentioned.
Study: 12640354
Drug: Cefaclor (CEF)
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor (CEF) 20 mg/kg/d for 10 days
Study: 12640354
Drug: Amoxicillin/clavulanate (AMC)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (AMC) 25 mg/kg/d for 10 days
Study: 9344167
Drug: Oral controlled-release
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral controlled-release (CR)
Study: 9344167
Drug: Transdermal (TDD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal (TDD)
Study: 9344167
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal (TMD)
Study: 8199078
Drug: Continuous oestrogen/progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oestrogen/progestin treatment
Study: 8199078
Drug: Cyclic sequential
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic sequential oestrogen/progestin treatment
Study: 8199078
Drug: Five years
Normalized name: HISTA-FIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five years treatment with oestradiol/norethisterone
Study: 2889258
Drug: Famotidine 5
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine 5 mg
Study: 19467049
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment at 440 degrees C for 30 min
Study: 19467049
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment at 440 degrees C for 10 min